Kristen Quigley

Chief Operating Officer at MOLECULAR TEMPLATES, INC.

53 year

Health Technology

Consumer Services

Profile

Kristen Quigley is currently the Chief Operating Officer at Molecular Templates, Inc. She started this position in 2023.
Prior to her current role, she worked as the Executive Director-Clinical Operations at Threshold Pharmaceuticals, Inc. Ms. Quigley completed her undergraduate degree at Washington University in St. Louis.

Kristen Quigley active positions

Companies	Position	Start
MOLECULAR TEMPLATES, INC.	Chief Operating Officer	2023-08-01

All active positions of Kristen Quigley

Former positions of Kristen Quigley

Companies	Position	End
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Chief Operating Officer	-

See the detail of Kristen Quigley's experience

Training of Kristen Quigley

Washington University in St. Louis

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kristen Quigley's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
MOLECULAR TEMPLATES, INC.	Health Technology

Private companies	1
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology